A novel inactivated virus system (InViS) for a fast and inexpensive assessment of viral disintegration.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 07 2022
Historique:
received: 25 04 2022
accepted: 24 06 2022
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

The COVID-19 pandemic has caused considerable interest worldwide in antiviral surfaces, and there has been a dramatic increase in the research and development of innovative material systems to reduce virus transmission in the past few years. The International Organization for Standardization (ISO) norms 18,184 and 21,702 are two standard methods to characterize the antiviral properties of porous and non-porous surfaces. However, during the last years of the pandemic, a need for faster and inexpensive characterization of antiviral material was identified. Therefore, a complementary method based on an Inactivated Virus System (InViS) was developed to facilitate the early-stage development of antiviral technologies and quality surveillance of the production of antiviral materials safely and efficiently. The InViS is loaded with a self-quenched fluorescent dye that produces a measurable increase in fluorescence when the viral envelope disintegrates. In the present work, the sensitivity of InViS to viral disintegration by known antiviral agents is demonstrated and its potential to characterize novel materials and surfaces is explored. Finally, the InViS is used to determine the fate of viral particles within facemasks layers, rendering it an interesting tool to support the development of antiviral surface systems for technical and medical applications.

Identifiants

pubmed: 35803968
doi: 10.1038/s41598-022-15471-5
pii: 10.1038/s41598-022-15471-5
pmc: PMC9270431
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11583

Informations de copyright

© 2022. The Author(s).

Références

Nanoscale. 2020 May 21;12(19):10703-10722
pubmed: 32374300
Rev Med Virol. 2019 Nov;29(6):e2074
pubmed: 31334909
J Gen Virol. 1992 Apr;73 ( Pt 4):995-8
pubmed: 1634881
Epidemiol Infect. 2020 Sep 29;148:e229
pubmed: 32988431
J Biomol Screen. 2009 Oct;14(9):1102-8
pubmed: 19726784
Front Microbiol. 2013 Mar 12;4:46
pubmed: 23487495
Nanomedicine (Lond). 2017 May;12(10):1119-1133
pubmed: 28447888
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Nanomedicine (Lond). 2020 Jun;15(15):1501-1512
pubmed: 32378459
Biochemistry. 1993 Oct 26;32(42):11330-7
pubmed: 8218197
J Appl Microbiol. 2018 May;124(5):1032-1046
pubmed: 29280540
Transl Psychiatry. 2018 Sep 20;8(1):193
pubmed: 30237468
J Hosp Infect. 2005 Jun;60(2):144-9
pubmed: 15866013
ACS Nano. 2020 Oct 27;14(10):12341-12369
pubmed: 33034443
EMBO J. 1990 Dec;9(13):4231-41
pubmed: 2265606
ACS Nano. 2020 Aug 25;14(8):9364-9388
pubmed: 32667191
Avian Pathol. 2004 Jun;33(3):303-6
pubmed: 15223557
Regul Toxicol Pharmacol. 2013 Dec;67(3):456-67
pubmed: 24080225
J Virol Methods. 2014 Mar;198:37-40
pubmed: 24388929
Appl Environ Microbiol. 2015 Nov;81(21):7610-4
pubmed: 26319879
Mater Sci Eng C Mater Biol Appl. 2020 Jul;112:110924
pubmed: 32409074
J Glob Infect Dis. 2020 May 22;12(2):47-93
pubmed: 32773996
J Nanobiotechnology. 2020 Mar 24;18(1):54
pubmed: 32209114
Nanotoxicology. 2013 Jun;7(4):402-16
pubmed: 22394310
Biochemistry. 1984 Nov 20;23(24):5675-81
pubmed: 6098295
J Biomed Sci. 2019 Sep 10;26(1):70
pubmed: 31500628
Am J Infect Control. 2020 Sep;48(9):1062-1067
pubmed: 32565272
J Pharm Sci. 2009 Sep;98(9):3340-57
pubmed: 19072857
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):61-6
pubmed: 21173278
Lancet Microbe. 2020 May;1(1):e10
pubmed: 32835322
Nat Nanotechnol. 2020 Aug;15(8):618-621
pubmed: 32728083
Nanoscale. 2018 Jul 5;10(25):11980-11991
pubmed: 29904776
Br J Dermatol. 1994 Jun;130(6):693-700
pubmed: 8011492
Nanoscale. 2016 Oct 06;8(39):17322-17332
pubmed: 27714104
Am J Infect Control. 2018 Jun;46(6):720-722
pubmed: 29550083

Auteurs

Lea A Furer (LA)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014, St. Gallen, Switzerland.

Pietro Clement (P)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014, St. Gallen, Switzerland.

Gordon Herwig (G)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, 9014, St. Gallen, Switzerland.

René M Rossi (RM)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Biomimetic Membranes and Textiles, 9014, St. Gallen, Switzerland.

Farien Bhoelan (F)

Mymetics BV, 2333 CH, Leiden, The Netherlands.

Mario Amacker (M)

Mymetics SA, 1066, Epalinges, Switzerland.

Toon Stegmann (T)

Mymetics BV, 2333 CH, Leiden, The Netherlands.
Department of Pulmonary Medicine, Bern University Hospital, University of Bern, 3012, Bern, Switzerland.

Tina Buerki-Thurnherr (T)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014, St. Gallen, Switzerland.

Peter Wick (P)

Empa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014, St. Gallen, Switzerland. peter.wick@empa.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH